Wednesday, September 20 2006 9:56 AM, EST
--------------------------------------------------------------------------------
EWKG, NNBP, LITL, DMSI - OTCStockExchange.com Stock Alert
M2 "Press Wire "
M2 PressWIRE - September 20, 2006 - Rochester, NY - OTCStockExchange.com's "Stock Watch Alert" this morning are Eurowork Global, Ltd. (Pink Sheets: EWKG), Nanobac Pharmaceuticals (OTCBB: NNBP), L International Computers Inc. (Pink Sheets: LITL), Dermisonics, Inc. (OTCBB: DMSI).
Sign-up for our FREE Stock Alerts at
http://www.otcstockexchange.com !
Eurowork Global, Ltd. (Pink Sheets: EWKG -
http://finance.yahoo.com/q?s=EWKG.PK ) Eurowork Global, Ltd. has approved a forward split of its shares at a 5 to 1 ratio. The split is scheduled to occur on September 25, 2006. Shareholders of record at close of the trading day prior to the split (September 22, 2006) will qualify.
"The timing and the synergy are favorable to issue a forward split to our shareholders," stated Joseph Pittera, President of Eurowork Global, Ltd. "Investor inquiries have increased, and the levels of trading are beginning to show signs of interest." "The levels of accepted visas are growing; this should provide a steady stream of guest workers in Spain well into next year."
EuroWork Global, Ltd. is a Public Holding Company engaged in the business of recruiting skilled and unskilled labor from Latin America, transporting them to Europe with legal work-visas, and placing them at jobs where they earn wages above what they would earn in their home countries.
Nanobac Pharmaceuticals (OTCBB: NNBP -
http://finance.yahoo.com/q?s=NNBP.OB ) Nanobac Pharmaceuticals, Incorporated, a bio-lifescience company, engages in the research and development of therapeutic and diagnostic technologies related to nanobacterium sanguineum. It also offers two diagnostic assays to identify the presence of Nanobacteria in blood, including NANO-CAPTURE for measuring levels of Nanobacterial antigen; and NANO-SERO for testing whether a patient has been exposed to Nanobacteria. Additionally, the company conducts biomedical research and clinical studies in the development of chronic prostatitis, kidney stones, and polycystic kidney diseases.
L International Computers Inc. (Pink Sheets: LITL -
http://finance.yahoo.com/q?s=LITL.PK ) L International Computers Inc., a renowned manufacturer of high-performance computers and personal technology, announced that it is evaluating listing of its Common Stock on the London Stock Exchange's Alternative Investment Market, or AIM.
The recently broadcast $45M agreement with UK-based Microscan International guaranteeing the European territory sales and marketing of L-branded products has moved the company into the international arena and increased its market awareness.
The company has begun an exhaustive evaluation of the listing requirements of the AIM and has had initial discussions with financial and brokerage companies.
The AIM gives companies from all countries and sectors access to the market at an earlier stage of their development, allowing them to experience life as a public company. Since AIM opened in 1995, more than 1,300 companies have been admitted and more than GBP 11 billion has been raised collectively.
Miguel Liebermann, CEO of L, commented, "Initial discussions with appropriate parties regarding an AIM listing were positive and we believe an opportunity to list would increase our viability and profile in the global market place."
Dermisonics, Inc. (OTCBB: DMSI -
http://finance.yahoo.com/q?s=DMSI.OB ) Dermisonics, Inc., a developer of painless injection-free ultrasonic transdermal drug-delivery patches and technologies with broad pharmaceutical and consumer applications, announced that it successfully completed its HPT-4 human pilot trial of its proprietary U-Strip transdermal drug-delivery system in patients with Type-2 diabetes.
Goal of Study -- This trial specifically examined the effects of the unique ultrasonic transmission utilized in the U-Strip insulin delivery system upon the skin of Type-2 diabetic patients. The goal of this study was to demonstrate that ultrasound alone, at levels used for ultrasonic drug delivery, does not cause skin damage or irritation.
Study Design -- The study was conducted upon 25 adult Type-2 diabetic patients of both sexes, with an average time on disease of at least 10 years. A blank transdermal patch (without insulin) was fitted on the left upper arm and the right side of the abdomen of each volunteer. The volunteers were tested over a five-hour test period, where ultrasound was applied continuously. The duration of the application of the ultrasound during the test period is greater than what is proposed for the application of insulin applied by U-Strip system. The U-Strip system produces an ultrasonic signal that is less than 1/5 the power of a ultrasonic toothbrush. The completed trial revealed no adverse skin reactions, no skin irritation or skin damage among any of the volunteers.
Results -- The trial revealed no adverse skin reactions, no skin irritation or skin damage among any of the volunteers. In a word, this study demonstrates that the ultrasound component of the U-Strip system does not damage the skin, even the skin of highly sensitive Type-2 diabetics.
Currently, people with diabetes rely on regular, frequent needle injections of insulin to control blood glucose levels. Dermisonics' proprietary U-Strip system employs proprietary microelectronics and ultrasonic technologies with a drug-carrying patch to enable the painless delivery of large-molecule drugs through the skin's natural pores and hair follicles.
Continuing Studies -- The Company is continuing its two other investigational review board (approved human pilot trials (HPT-2 and HPT-3) to further demonstrate the efficacy of the U-Strip system. HPT-3 is designed to demonstrate that wearing the insulin patch will not damage the skin of the patient; HPT-4 is designed to demonstrate the ability of the U-Strip System the to deliver controlled doses of insulin to patients, comparing the rate of delivery of insulin in comparison to an insulin pump. The Company anticipates announcing the results of HPT-3 before the end of September 2006. The Company anticipated completion of HPT 2 by the end of 2006.
About OTCStockExchange.com
OTCStockExchange.com (OTCS) is a leading investor relations firm whose primary focus is promoting awareness among brokers, investors, and others in the investment community who are interested in small and micro-cap companies. OTCS is dedicated to helping publicly traded companies gain the exposure they need to move forward with the development of their business plans. OTCS's goal is to feature equity investments in micro or small capitalization companies that have the potential for long-term appreciation. OTCS provides all investors with the latest news, press releases, investment opinions, and research reports for all the companies highlighted on the site. OTCS offers a free financial newsletter. To subscribe or get more information, visit our home page located at
http://www.otcstockexchange.com .
We offer many investor relations programs to public companies. To feature a company on our web site or in our daily Newsletter or Mid-Day Stock Alert, please contact Chris Wheeler at 585-330-8514 , or via email at
info@otcstockexchange.com .
Affiliates of the publisher for OTCS are to receive a fee of 10,000 shares per week from one or more third party shareholders of Eurowork Global, Ltd. (Pink Sheets: EWKG) for this website feature.
OTCS's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event of a rise in value. OTCS will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
OTCStockExchange.com (OTCS) based upon information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by OTCS to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. OTCS is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on
http://www.otcstockexchange.com or mentioned herein. OTCS has been compensated by third party shareholders or with cash from the company on behalf of one or more of the companies mentioned in this opinion.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and OTCS undertakes no obligation to update such statements.
((Comments on this story may be sent to
info@m2.com))
آ© 2006 M2 COMMUNICATIONS LTD